Abstracts tagged "obesity"

Abstract Number: 0153 • ACR Convergence 2022
Obesity Is Associated with Higher Odds of Malignancy Development Among Dermatomyositis Patients
Astia Allenzara¹, Nakisa Sadeghi¹, Carolina Alvarez², Steve Maczuga³, Matthew Helm³, Amanda Nelson² and Galen Foulke¹, ¹University of North Carolina, Chapel Hill, NC, ²University of North Carolina at Chapel Hill, Chapel Hill, NC, ³Penn State Hershey Medical Center, Hershey, PA
Background/Purpose: Dermatomyositis (DM) is an idiopathic inflammatory myopathy with an increased risk of mortality and morbidity from cancer. Across the general population, excess body weight…
Abstract Number: 2234 • ACR Convergence 2022
Obesity, Adipokines, and Chronic and Persistent Pain in Rheumatoid Arthritis
Joshua Baker¹, Kristin Wipfler², Marianna Olave³, Sofia Pedro⁴, Patricia Katz⁵ and Kaleb Michaud⁶, ¹University of Pennsylvania, Philadelphia, PA, ²FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ³Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, ⁴Forward, The National Databank for Rheumatic Diseases, Wichita, KS, ⁵UCSF, San Rafael, CA, ⁶University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Obesity has been linked to chronic pain and pain sensitization in the general population and among patients with rheumatoid arthritis (RA). The mechanism by…
Abstract Number: 0291 • ACR Convergence 2022
Tofacitinib Leads to Significant Weight Gain – A Real Life Experience of 429 Patients
Naga Prabu¹, velammal petchaippan², Gayathri anand³, Aswathi kumar¹ and Saranya Ramachandiran³, ¹SAKTHI RHEUMATOLOGY CENTRE PVT LTD, Coimbatore, India, ²PSG INSTTUTE OF MEDICAL SCIENCES AND RESEARCH, Coimbatore, India, ³sakthi rheumatology centre pvt l;td, Coimbatore, India
Background/Purpose: Tofacitinib(Tofa) an oral Janus kinase inhibitor(JAK) has shown good promise in the management of rheumatoid arthritis and psoriatic arthritis. While being increasingly used in…
Abstract Number: 0405 • ACR Convergence 2022
Efficacy and Safety of Tofacitinib in Patients with Ankylosing Spondylitis by Baseline BMI: A Post Hoc Analysis of Phase 2 and Phase 3 Trials
Hillary Norton¹, Paula Sliwinska-Stanczyk², Tomas Hala³, Bassel Elzorkany⁴, Lori Stockert⁵, Harry Shi⁵, Cunshan Wang⁶, Jerome Paulissen⁷ and Christopher Ritchlin⁸, ¹Sante Fe Rheumatology, Santa Fe, NM, ²Reumatika Centrum Reumatologii, Warsaw, Poland, ³Center for Clinical and Basic Research, Pardubice, Czech Republic, ⁴Department of Rheumatology, Cairo University, Cairo, Egypt, ⁵Pfizer, Inc, Collegeville, PA, ⁶Pfizer Inc, Groton, CT, ⁷Pfizer Inc, New York, NY, ⁸Allergy, Immunology and Rheumatology Division, University of Rochester Medical School, Canandaigua, NY
Background/Purpose: Higher BMI is associated with reduced response to TNF inhibitors (TNFi) in patients (pts) with AS.1 Tofacitinib is an oral Janus kinase inhibitor for…
Abstract Number: 0680 • ACR Convergence 2022
Association of Environmental Risk Factors with Antiphospholipid Antibodies and Thrombosis in 1199 International Patients Referred for Suspected Antiphospholipid Syndrome
Medha Barbhaiya¹, Deanna Jannat-Khah, DrPH, MSPH¹, Jonah Levine¹, Karen Costenbader² and Doruk Erkan¹, ¹Hospital for Special Surgery, New York, NY, ²Brigham and Women's Hospital, Boston, MA
Background/Purpose: Whether environmental risk factors induce antiphospholipid antibody (aPL) positivity and increase the risk of arterial thrombosis (AT) and venous thromboembolism (VTE) in aPL-positive patients…
Abstract Number: 0706 • ACR Convergence 2022
Association Between Metabolic Syndrome and Knee Pain over 10-13 Years in Middle-Aged Adults
Ambrish Singh, Brooklyn Fraser, Alison Venn, Leigh Blizzard, Changhai Ding and Benny Samuel Antony, Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia
Background/Purpose: Metabolic syndrome (MetS) is characterised by the clustering of central obesity with metabolic abnormalities. MetS has been suggested as having a role in osteoarthritis…
Abstract Number: 0741 • ACR Convergence 2022
Prescribing Patterns of SGLT2 Inhibitors for Patients with Autoimmune Rheumatic Disease
Emily G Oakes¹, Jack Ellrodt¹, May Choi², Hongshu Guan¹ and Karen Costenbader¹, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital | University of Calgary, Calgary, AB, Canada
Background/Purpose: Sodium-glucose co-transporter 2 inhibitors (SGLT2i, dapagliflozin, canagliflozin, and empagliflozin) are a class of oral hypoglycemic medication for management of Type II diabetes mellitus (T2D),…
Abstract Number: 0821 • ACR Convergence 2022
Imiquimod Exaggerates Obesity-associated Adipose Tissue Inflammation in Murine Psoriasis Model
Hee Joo Kim¹, Dong Il Jeong² and YunJae Jung³, ¹Department of Dermatology, Gachon Gil Medical Center, Gachon University College of Medicine, Incheon, Republic of Korea, ²Department of Dermatology, Gachon University Gil Medical Center, Incheon, Republic of Korea, ³Department of Microbiology, Gachon University College of Medicine, Incheon, Republic of Korea
Background/Purpose: Recently, obesity has been known to be associated with psoriasis: obesity has negative effects on the prevalence, severity, and treatment response of psoriasis. High…
Abstract Number: 0844 • ACR Convergence 2022
Differences in Skin Advanced Glycation End-Products Levels Between Subgroups of Achilles Tendinopathy
Hayley Powell Smitheman, Shawn L. Hanlon and Karin Grävare Silbernagel, University of Delaware, Newark, DE
Background/Purpose: Achilles tendinopathy is a painful debilitating injury that negatively affects physical activity, quality of life, and overall health. While exercise is considered the gold…
Abstract Number: 0889 • ACR Convergence 2022
Serum Adipokines Predict Incident Osteoporotic Fracture in Patients with Rheumatoid Arthritis
Joshua Baker¹, Katherine Wysham², Bryant England³, Punyasha Roul⁴, Aleksander Lenert⁵, Grant Cannon⁶, Brian Sauer⁷, Geoffrey Thiele³ and Ted Mikuls⁸, ¹University of Pennsylvania, Philadelphia, PA, ²VA Puget Sound/University of Washington, Seattle, WA, ³University of Nebraska Medical Center, Omaha, NE, ⁴UNMC, Omaha, NE, ⁵University of Iowa, Iowa City, IA, ⁶Retired, Salt Lake City, UT, ⁷Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁸Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Adipokines are fat and muscle-secreted protein hormones that regulate metabolism. Adiponectin has been associated with fracture in the general population while the role of…
Abstract Number: 1040 • ACR Convergence 2022
Impact of Weight and Sex on Long-term Persistence to Secukinumab Treatment in Patients with Active Psoriatic Arthritis or Ankylosing Spondylitis
Uta Kiltz¹, Petros P. Sfikakis², Nicola Gullick³, ATHINA THEODORIDOU⁴, Anna Kandyli⁵, Jan Brandt-Juergens⁶, Philippe Goupille⁷, Nicola Maiden⁸, Karl Gaffney⁹, Daniel Peterlik¹⁰, Barbara Schulz¹¹, Effie Pournara¹¹ and Piotr Jagiello¹¹, ¹Rheumazentrum Ruhrgebiet, Herne, Germany, ²Joint Academic Rheumatology Program, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece, ³University Hospital Coventry & Warwickshire; Warwick Medical School, University of Warwick, Coventry, United Kingdom, ⁴Euromedica Geniki Kliniki, General Hospital, Thessaloniki, Greece, ⁵Rheumatology Outpatient Clinic, Iaso General Hospital, Athens, Greece, ⁶Rheumatologische Schwerpunktpraxis, Berlin, Germany, ⁷Rheumatology department, University Hospital of Tours, Tours, France, ⁸Craigavon Area Hospital, Southern Health & Social Care Trust, Craigavon, United Kingdom, ⁹Norfolk and Norwich University Hospital NHS Trust, Norfolk, United Kingdom, ¹⁰Novartis Pharma GmbH, Nürnberg, Germany, ¹¹Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Secukinumab (SEC) has demonstrated a high sustained response rate in patients (pts) with psoriatic arthritis (PsA) or ankylosing spondylitis (AS) across Phase III clinical…
Abstract Number: 1187 • ACR Convergence 2022
Obesity Burden and Effects of Apremilast on Changes in Cardiometabolic Parameters by Obesity Status in Patients with Psoriasis (PsO) or Psoriatic Arthritis (PsA) in a Real-World Setting
Kate Orroth¹, Cristi Cavanaugh², Xi Qian², Pam Kumparatana², Yuri Klyachkin³, Stephen Colgan⁴ and Myriam Cordey⁴, ¹Amgen, Manhattan Beach, CA, ²OM1, Inc., Boston, MA, ³Amgen, Lexington, KY, ⁴Amgen, Inc., Thousand Oaks, CA
Background/Purpose: Obesity prevalence is higher in patients with PsO and PsA than the general population. Weight loss may improve PsO disease severity in obese patients.…
Abstract Number: 1289 • ACR Convergence 2022
Evaluating Peri–operative Preferences of Bariatric Surgeons in the Management of Immunosuppressive Therapy During Bariatric Surgery
Suguni Aushadhi Loku Galappaththy¹ and Nicole Fearing², ¹University of Missouri Kansas City, Kansas City, MO, ²HCA Menorah Medical Center, Overland Park, KS
Background/Purpose: As the number of bariatric procedures increases, surgeons will encounter more patients on long-term immunosuppressive medications that may increase post-operative complications. Currently, there are…
Abstract Number: 1328 • ACR Convergence 2022
CT Evaluation of Bone Fragility 2 Years After Bariatric Surgery in Patients with Obesity: An Observational Study
Marine FAUNY¹, Marion Halin², Edem Allado², Didier Quilliot², Laurent Brunaud², Eliane Albuisson², Isabelle Chary-Valckenaere² and Damien Loeuille², ¹Nancy University Hospital, Toul, France, ²Nancy University Hospital, Vandoeuvre, France
Background/Purpose: The objectives were to evaluate bone fragility on computed tomography (CT) in patients with obesity before and 2 years after bariatric surgery and to…
Abstract Number: 1329 • ACR Convergence 2022
Prevalence of Bone Fragility on DXA and CT in Patients with Obesity
Marion Halin¹, Edem Allado¹, Didier Quilliot¹, Eliane Albuisson¹, Isabelle Chary-Valckenaere¹, Damien Loeuille¹, Laurent Brunaud¹ and Marine FAUNY², ¹Nancy University Hospital, Vandoeuvre, France, ²Nancy University Hospital, Toul, France
Background/Purpose: Primary objective was to evaluate bone fragility prevalence on dual X-ray absorptiometry (DXA) and on computed tomography (CT), in patients with severe obesity. Secondary…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].